DeNardo G L, Raventos A, Hines H H, Scheibe P O, Macey D J, Hays M T, DeNardo S J
Int J Radiat Oncol Biol Phys. 1985 Feb;11(2):335-48. doi: 10.1016/0360-3016(85)90156-7.
Cancer-seeking antibodies carrying radionuclides can, in theory, be very powerful agents for the radiotherapy of cancer. However, as with all radiotherapy, the undesired dose to critical normal organs is the limiting factor that determines success or failure. The distribution of radiation dose in cancer and noncancer tissue is highly dependent on choices the therapist can make: choices of the antigens to be targeted, choices of the antibodies or antibody fragments to be used, choices of radionuclides, of amounts, of timing, and other electives. New technologies, especially of monoclonal antibody production, make the options myriad. Optimization of this therapy depends on a foreknowledge of the radiation dose distributions to be expected. The necessary data can be acquired by established tracer techniques, in individual patients, for particular treatment selections. These tracer techniques can now be implemented by advanced equipment for quantitative, tomographic radionuclide imaging and strengthened by dynamic modeling of the physiological parameters which govern radionuclide distribution, and hence radiation dose distribution.
携带放射性核素的寻癌抗体理论上可以成为癌症放射治疗的强大手段。然而，与所有放射治疗一样，关键正常器官所接受的非预期剂量是决定成败的限制因素。癌症组织和非癌组织中的辐射剂量分布在很大程度上取决于治疗师可做出的选择：靶向抗原的选择、所用抗体或抗体片段的选择、放射性核素的选择、用量的选择、给药时间的选择以及其他选择。新技术，尤其是单克隆抗体制备技术，使得选择众多。这种治疗方法的优化取决于对预期辐射剂量分布的预先了解。必要的数据可以通过既定的示踪技术，针对个体患者的特定治疗选择来获取。现在，这些示踪技术可以通过先进的定量断层放射性核素成像设备来实施，并通过对控制放射性核素分布（进而控制辐射剂量分布）的生理参数进行动态建模得到加强。
